Vivo Bio Tech Launches State-of-the-art Large Animal Facility

Vivo Bio Tech Limited has successfully secured approval from the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), obtained funding from a financial institution, and completed the development of a 15,000 sq. ft. large animal facility. This advanced facility, co-funded through internal accruals and institutional debt, is designed to house, breed, and conduct studies on canines, pigs, mini-pigs, sheep, and goats. The facility offers a wide range of services, including Pharmacokinetic (PK), Pharmacodynamic (PD), Surgical Studies, and Toxicology Studies, and is already providing these services to an expanding list of major pharmaceutical and bio-pharmaceutical companies. This new capability significantly strengthens Vivo Bio Tech’s existing ecosystem, which encompasses In-vitro and In-vivo Small Animal Studies, Eco-Toxicology, Analytical, and Bio-analytical services. The addition of this large animal facility enables Vivo Bio Tech to deliver comprehensive Investigational New Drug (IND) packages to pharmaceutical and biotech companies worldwide, positioning itself as a joint discovery partner for large pharmaceutical organizations.